- Leading clinicians presented new evidence on treatment options for patients suffering from Rett syndrome and treatment resistant schizophrenia
- Company provided update on its
Luxembourg and Milan – October 30, 2018 – The European Investment Bank (EIB) and Newron Pharmaceuticals S.p.A. (“Newron") (SIX: NWRN), a biopharmaceutical company focused on the
Milan, Italy, October 23, 2018 – Newron Pharmaceuticals S.p.A. (“Newron") (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Leading clinicians in the fields of schizophrenia and Rett syndrome, John Kane, MD and Daniel Glaze, MD to present at research and investor update event
Milan, Italy and
Families come together to share patient experience and treatment needs at an international conference in Rome, Italy
Milan, Italy and Morristown, NJ, USA – October 8, 2018 -
Milan, Italy and Morristown, NJ, USA – September 25, 2018 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel
Milan, Italy – September 13, 2018 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients
Milan, Italy and Morristown, NJ, USA – September 12, 2018 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel
Milan, Italy and Morristown, NJ, USA – August 1, 2018 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel
Trial now expected to complete enrollment in H2 2018, with data readout expected in H1 2019
90% of patients have continued into a long-term extension study
Rett syndrome is an
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
